Identification of B7 family members (B7-1 and B7-2) and their receptors (CD28 and CTLA4) has provided important insights into molecular mechanisms for regulation of immune responses, and perhaps more importantly, several novel approaches to tumor immunotherapy. Under the support of the previous grant, the investigator's laboratory has made significant progress in the last three and a half years in understanding the structural basis of B7-B7-CTLA4 interaction, the role of B7 at the effector phase of anti-tumor immunity, and in the function of B7-CTLA4 interaction. In the next funding period, the investigator will continue to focus on the role of B7 receptors in immune regulation and tumor immunotherapy. He will identify the receptors responsible for the effector function of B7, and explore the means by which the requirement for B7 at the effector phase can be bypassed. The investigator will also determine whether the immune regulatory function of the B7-CTLA4 interaction is exerted during the development or the activation of T cells. Moreover, they will produce mice with a humanized CTLA4 molecule, and use them to screen for immunotherapeutic mAbs, and to determine the mechanism by which anti-CTLA4 mAb induces protective immunity. In order to achieve these goals, they will need to engineer T cell lineage-specific and stage-specific targeted mutation of the CTLA4 gene. They will also need to produce mice with human CTLA4 gene knock-in mice. In combination with the WT and mutant B7-1 molecules and transgenic mice produced in the last funding period, they will be able to carry out definitive analysis of the function of B7 receptors, CD28 and CTLA4, in development activation and effector function of tumor-reactive T lymphocytes. More importantly, the proposed studies will provide animal models that can be used to screen monoclonal antibodies that are of therapeutic value for human cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA069091-08
Application #
6512791
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Mccarthy, Susan A
Project Start
1996-07-01
Project End
2004-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
8
Fiscal Year
2002
Total Cost
$409,313
Indirect Cost
Name
Ohio State University
Department
Pathology
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Wang, Yin; Liu, Yan; Wu, Cindy et al. (2006) Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell 10:179-90
Kocak, Ergun; Lute, Kenneth; Chang, Xing et al. (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 66:7276-84
Yang, Tianyu; Lapinski, Philip E; Zhao, Haotian et al. (2005) A rare transporter associated with antigen processing polymorphism overpresented in HLAlow colon cancer reveals the functional significance of the signature domain in antigen processing. Clin Cancer Res 11:3614-23
May Jr, Kenneth F; Roychowdhury, Sameek; Bhatt, Darshna et al. (2005) Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood 105:1114-20
Zheng, Xincheng; Yin, Lijie; Liu, Yang et al. (2004) Expression of tissue-specific autoantigens in the hematopoietic cells leads to activation-induced cell death of autoreactive T cells in the secondary lymphoid organs. Eur J Immunol 34:3126-34
Luo, Liqun; Chapoval, Andrei I; Flies, Dallas B et al. (2004) B7-H3 enhances tumor immunity in vivo by costimulating rapid clonal expansion of antigen-specific CD8+ cytolytic T cells. J Immunol 173:5445-50
Gao, Jian-Xin; Chang, Xing; Zheng, Xincheng et al. (2004) A new role for CD28 in the survival of autoreactive T cells in the periphery after chronic exposure to autoantigen. Int Immunol 16:1403-9
Liu, Xingluo; Gao, Jian Xin; Wen, Jing et al. (2003) B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J Exp Med 197:1721-30
Yang, Tianyu; McNally, Beth A; Ferrone, Soldano et al. (2003) A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem 278:15291-6
Gao, Jian-Xin; Liu, Xingluo; Wen, Jing et al. (2003) Two-signal requirement for activation and effector function of natural killer cell response to allogeneic tumor cells. Blood 102:4456-63

Showing the most recent 10 out of 26 publications